Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.
Evan Y Yu, Christian Gratzke, Mauricio Burotto, Alison Y Zhang, Eric Lévesque, Francisco Ortega, Avivit Peer, Donald Vile, Zheng Hong Chen, Yue Song, Charles Schloss, Jelena Todoric, Chris Garratt, Christian Poehlein, Emmanuel S Antonarakis, Karim Fizazi
Future Oncol 22(7) 765-772
摘要
摘要
Treatment options for metastatic castration-resistant prostate cancer (mCRPC) include androgen receptor pathway inhibitors (ARPIs), taxanes, radium-223, Lu-PSMA, poly (ADP-ribose) polymerase inhibitors, and immunotherapy in select patients. Resistance to ARPIs and hormone-based therapies has been associated with AR-ligand-binding domain mutations that can lead to promiscuous stimulation by other steroid hormones. There is a need to explore alternative targets and develop next-generation ARPIs or combination therapies that overcome this resistance. We describe the rationale and design of the randomized phase III trials OMAHA-003 (NCT06136624) and OMAHA-004 (NCT06136650), which will evaluate the efficacy and safety of opevesostat, a steroidogenesis inhibitor, versus ARPI switch in previously treated mCRPC. Results may support opevesostat as a potential new treatment option for mCRPC.Clinical trial registration: www.clinicaltrials.gov identifiers are NCT06136624 and NCT06136650.
KM 提取结果
0 个 Figure · 0 个 KM 面板